Scarica l'app Stockscreener
4.49
0.22%
0.010
Dopo l'orario di chiusura:
4.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.48
Aprire:
$4.53
Volume 24 ore:
178.32K
Relative Volume:
0.82
Capitalizzazione di mercato:
$186.77M
Reddito:
$2.00M
Utile/perdita netta:
$109.16M
Rapporto P/E:
1.738
EPS:
2.5835
Flusso di cassa netto:
$-9.11M
1 W Prestazione:
-5.07%
1M Prestazione:
-11.44%
6M Prestazione:
+31.29%
1 anno Prestazione:
+78.62%
Intervallo 1D:
$4.39
$4.565
Intervallo di 1 settimana:
$4.39
$4.795
Portata 52W:
$2.09
$5.47
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
4.49 | 196.76M | 2.00M | 109.16M | -9.11M | 2.5835 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
A trading plan underpins an officer's proposed $140K share sale at Oramed (ORMP). - Stock Titan
40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan
Six option grants were canceled in exchange for a fully vested stock award to Oramed (ORMP) CEO Nadav Kidron. - Stock Titan
Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu - Barchart.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com
Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS
Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com
Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportLate Stage Breakouts - siam.in
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
Oramed Pharmaceuticals Inc. (ORMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Yahoo Finance
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - The Manila Times
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsSpring Pattern - dars.gov.et
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
ORMP Q4 2025 Earnings: Profitable Quarter on Non-Operating Income as Stock RisesEstimate Revision Count - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):